LON:APTA Aptamer Group 10/22/2024 Earnings Report GBX 0.39 -0.01 (-1.77%) As of 07/18/2025 10:56 AM Eastern ProfileEarnings History Aptamer Group EPS ResultsActual EPSGBX 0.71Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AAptamer Group Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAptamer Group Announcement DetailsQuarterDate10/22/2024TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Aptamer Group Earnings HeadlinesAptamer Group raises £2 million to fund investment driveJuly 8, 2025 | msn.comAptamer Group’s Non-Executive Director Increases Stake with Share PurchaseJanuary 13, 2025 | tipranks.comThe big winner of Crypto week?It’s Crypto Week at the White House — and the sector is moving from fringe to full-scale adoption. With Bitcoin hitting $123,000 and giants like BlackRock and Fidelity pouring in, one expert believes a lesser-known coin could soon be vaulted to the top — possibly even landing in the government’s digital reserve.July 20 at 2:00 AM | Weiss Ratings (Ad)Aptamer Group CEO Boosts Stake with Share PurchaseDecember 9, 2024 | tipranks.comSee More Aptamer Group Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aptamer Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aptamer Group and other key companies, straight to your email. Email Address About Aptamer GroupAptamer Group (LON:APTA) is a leading provider of aptamer selection services and developer of aptamer-based reagents for use in research, bioprocessing, diagnostic, and therapeutic applications. Headquartered in York, UK, the Company partners globally to deliver aptamer-based solutions that drive discovery and development across the life sciences. Aptamer Group has developed the proprietary Optimer® platform technology that drives three distinct businesses: Aptamer Solutions, Aptamer Diagnostics and Aptamer Therapeutics. Through the use of its Optimer platform the Company aims to enable new opportunities, including discovery and development partnerships for improved biologic drugs, and new applications, such as novel assays and targets, to accelerate discovery and improve current standard processes. For more information, visit: https://aptamergroup.com/View Aptamer Group ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings Report Upcoming Earnings NXP Semiconductors (7/21/2025)Verizon Communications (7/21/2025)Comcast (7/22/2025)Intuitive Surgical (7/22/2025)Texas Instruments (7/22/2025)America Movil (7/22/2025)Chubb (7/22/2025)Canadian National Railway (7/22/2025)Capital One Financial (7/22/2025)Danaher (7/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
